Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL JAMES DOWNING

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1639159346
CMS profile
300554
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$327.48

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $327.48 15

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL JAMES DOWNING

NPI 1639159346 · CMS profile ID 300554

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $327.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $15.5112/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686585003 CMS
Neurocrine Biosciences, Inc. $18.1411/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693124787 CMS
Indivior Inc. $16.0410/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705775213 CMS
Alkermes, Inc. $12.1409/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686585005 CMS
Alkermes, Inc. $14.0608/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686585001 CMS
Janssen Pharmaceuticals, Inc $19.5708/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658527621 CMS
Indivior Inc. $12.0707/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705775211 CMS
JAZZ PHARMACEUTICALS INC. $12.7007/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684174127 CMS
Allergan Inc. $17.5207/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670271099 CMS
Indivior Inc. $20.1306/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705775209 CMS
Takeda Pharmaceuticals U.S.A., Inc. $99.4705/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682109013 CMS
Lundbeck LLC $12.3804/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684293419 CMS
Janssen Pharmaceuticals, Inc $25.0203/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658527615 CMS
Alkermes, Inc. $18.5803/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686584999 CMS
Allergan Inc. $14.1501/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670271096 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $327.48 15
PY2020 $163.49 9
PY2021 $551.28 27
PY2022 $399.89 22
PY2023 $626.73 20
PY2024 $647.99 23
PY2025 $847.36 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $914,450.61 88
PY2024 Recipient $2,949.66 2
PY2024 Principal investigator $1,362,460.91 98
PY2023 Recipient $59,611.81 14
PY2023 Principal investigator $997,596.68 181
PY2022 Principal investigator $897,046.39 115
PY2021 Principal investigator $714,455.57 113
PY2020 Principal investigator $1,352,717.69 219
PY2019 Recipient $157,177.13 20
PY2019 Principal investigator $1,373,636.72 268

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

219 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $384.50 12/31/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721314623
Principal investigator 1 Allergan, Inc. $4,314.92 12/31/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721316063
Principal investigator 1 Allergan, Inc. $4,421.39 12/31/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721316917
Principal investigator 1 Janssen Research & Development, LLC $2,065.00 12/31/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 719498495
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 12/31/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 719498499
Principal investigator 1 Janssen Research & Development, LLC $2,580.00 12/31/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 719498511
Principal investigator 1 Janssen Research & Development, LLC $3,072.00 12/31/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 719498515
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 12/31/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 719498519
Principal investigator 1 Eisai Inc. $3,117.00 12/29/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749134573
Principal investigator 1 Eisai Inc. $1,896.70 12/29/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749134575
Principal investigator 1 Eisai Inc. $1,896.70 12/29/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749134577
Principal investigator 1 Allergan, Inc. $10,269.50 12/23/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721313919
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,517.82 12/23/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749583907
Principal investigator 1 ACADIA Pharmaceuticals Inc $8,610.03 12/21/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-059 No dispute reported 06/30/2026 748385333
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,000.00 12/21/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-066 No dispute reported 06/30/2026 748385335
Principal investigator 1 Janssen Research & Development, LLC $6,854.00 12/17/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 719498565
Principal investigator 1 Sage Therapeutics, Inc. $500.00 12/17/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749046221
Principal investigator 1 Sage Therapeutics, Inc. $6,500.00 12/17/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749046239
Principal investigator 1 Allergan, Inc. $12,735.70 12/15/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721312539
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $3,692.65 12/11/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 748986561
Principal investigator 1 Sage Therapeutics, Inc. $29,528.01 12/09/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749045859
Principal investigator 1 Sage Therapeutics, Inc. $5,805.09 12/09/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749045861
Principal investigator 1 Janssen Research & Development, LLC $3,020.00 12/07/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 719498503
Principal investigator 1 Janssen Research & Development, LLC $500.00 12/07/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 719498507
Principal investigator 1 Adlon Therapeutics L.P. $10,626.70 12/01/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ADA4003 No dispute reported 06/30/2026 748841315
Principal investigator 1 Boehringer Ingelheim International GmbH $1,970.42 12/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906307
Principal investigator 1 Boehringer Ingelheim International GmbH $1,970.42 12/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906309
Principal investigator 1 Boehringer Ingelheim International GmbH $1,970.42 12/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906311
Principal investigator 1 Boehringer Ingelheim International GmbH $1,970.42 12/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906313
Principal investigator 1 Supernus Pharmaceuticals, Inc. $441.51 11/28/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749583731
Principal investigator 1 Janssen Research & Development, LLC $12,356.00 11/26/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 719498561
Principal investigator 1 Allergan, Inc. $16,028.40 11/23/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721309597
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,112.89 11/20/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 748385155
Principal investigator 1 Allergan, Inc. $7,387.20 11/19/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721309087
Principal investigator 1 Adlon Therapeutics L.P. $5,000.00 11/13/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ADA4003 No dispute reported 06/30/2026 748841303
Principal investigator 1 Sage Therapeutics, Inc. $500.00 11/12/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749045725
Principal investigator 1 ITI, Inc. $162.00 11/10/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 750026609
Principal investigator 1 ITI, Inc. $25.00 11/10/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 750026611
Principal investigator 1 Allergan, Inc. $1,000.00 11/09/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721307081
Principal investigator 1 ACADIA Pharmaceuticals Inc $7,008.71 11/05/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-059 No dispute reported 06/30/2026 748385083
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 11/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906295
Principal investigator 1 Supernus Pharmaceuticals, Inc. $5,479.70 10/29/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749583545
Principal investigator 1 Janssen Research & Development, LLC $7,030.00 10/23/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 719498557
Principal investigator 1 Allergan, Inc. $500.00 10/21/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721304593
Principal investigator 1 Sage Therapeutics, Inc. $8,565.57 10/21/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749045309
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,956.15 10/20/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 748385029
Principal investigator 1 Allergan, Inc. $327.00 10/20/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721303935
Principal investigator 1 Eisai Inc. $1,665.00 10/20/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749135453
Principal investigator 1 Eisai Inc. $1,600.00 10/20/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749135455
Principal investigator 1 Eisai Inc. $2,648.10 10/20/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749135457
Principal investigator 1 Sage Therapeutics, Inc. $54,307.89 10/14/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749045033
Principal investigator 1 ITI, Inc. $1,500.00 10/08/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 750026355
Principal investigator 1 ITI, Inc. $80.00 10/08/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 750026361
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906305
Principal investigator 1 ITI, Inc. $232.00 10/01/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 750026273
Principal investigator 1 ITI, Inc. $3,452.00 10/01/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 750026277
Principal investigator 1 ITI, Inc. $3,452.00 10/01/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 750026279
Principal investigator 1 ITI, Inc. $1,017.00 10/01/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 750026281
Principal investigator 1 ITI, Inc. $1,017.00 10/01/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 750026283
Principal investigator 1 ITI, Inc. $724.00 10/01/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 750026285
Principal investigator 1 ITI, Inc. $232.00 10/01/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 750026309
Principal investigator 1 Janssen Research & Development, LLC $10,181.00 09/24/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 719498555
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,320.65 09/21/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 748384749
Principal investigator 1 ACADIA Pharmaceuticals Inc $866.70 09/21/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-059 No dispute reported 06/30/2026 748384821
Principal investigator 1 Allergan, Inc. $371.00 09/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721298025
Principal investigator 1 Allergan, Inc. $86.00 09/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721298081
Principal investigator 1 Allergan, Inc. $4,521.05 09/17/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721298341
Principal investigator 1 Allergan, Inc. $10,000.00 09/10/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721296553
Principal investigator 1 ACADIA Pharmaceuticals Inc $27,024.50 09/07/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-059 No dispute reported 06/30/2026 748384685
Principal investigator 1 Sage Therapeutics, Inc. $50.00 09/03/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749044479
Principal investigator 1 Allergan, Inc. $700.00 09/01/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721294601
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 09/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906301
Principal investigator 1 Eisai Inc. $1,600.00 09/01/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749134297
Principal investigator 1 Eisai Inc. $3,371.00 09/01/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749135475
Principal investigator 1 Eisai Inc. $3,117.00 09/01/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749135477
Principal investigator 1 Eisai Inc. $4,121.00 09/01/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749135483
Principal investigator 1 Eisai Inc. $1,600.00 09/01/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749135485
Principal investigator 1 Eisai Inc. $1,600.00 09/01/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749135487
Principal investigator 1 Allergan, Inc. $1,167.55 08/31/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721294123
Principal investigator 1 Janssen Research & Development, LLC $6,027.00 08/27/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 719498551
Principal investigator 1 Supernus Pharmaceuticals, Inc. $16,631.28 08/27/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749583215
Principal investigator 1 Sage Therapeutics, Inc. $28,714.86 08/26/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749044275
Principal investigator 1 Allergan, Inc. $371.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721292683
Principal investigator 1 Allergan, Inc. $315.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721292855
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,956.15 08/19/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 748384545
Principal investigator 1 Allergan, Inc. $5,059.95 08/11/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721289483
Principal investigator 1 Sage Therapeutics, Inc. $634.92 08/06/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749044001
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906303
Principal investigator 1 Eisai Inc. $1,665.00 07/31/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749134187
Principal investigator 1 Eisai Inc. $1,600.00 07/31/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749134189
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.00 07/31/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737085937
Principal investigator 1 Janssen Research & Development, LLC $10,313.00 07/27/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 719498547
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 07/24/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737085643
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 07/24/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737085645
Principal investigator 1 Allergan, Inc. $10,440.50 07/22/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721286253
Principal investigator 1 Sage Therapeutics, Inc. $35,034.22 07/22/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749043741
Principal investigator 1 Allergan, Inc. $110.00 07/21/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721285989
Principal investigator 1 Allergan, Inc. $3,000.00 07/21/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721285991
Principal investigator 1 Allergan, Inc. $1,547.00 07/21/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721286055
Principal investigator 1 ACADIA Pharmaceuticals Inc $8,240.12 07/20/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 748384316
Principal investigator 1 Allergan, Inc. $500.00 07/20/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721285201
Principal investigator 1 Eisai Inc. $22,096.60 07/16/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749134429
Principal investigator 1 Allergan, Inc. $4,631.90 07/14/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721283675
Principal investigator 1 Supernus Pharmaceuticals, Inc. $6,304.28 07/14/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF SPN-812 ER FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 749582907
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 07/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906297
Principal investigator 1 Supernus Pharmaceuticals, Inc. $5,264.27 07/01/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 749582831
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.00 06/30/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737084233
Principal investigator 1 Janssen Research & Development, LLC $9,672.00 06/25/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 719498543
Principal investigator 1 Sage Therapeutics, Inc. $24,292.71 06/24/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749043441
Principal investigator 1 Allergan, Inc. $1,000.00 06/17/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721280471
Principal investigator 1 Allergan, Inc. $1,349.95 06/16/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721280005
Principal investigator 1 Sage Therapeutics, Inc. $2,250.00 06/04/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749043223
Principal investigator 1 Sage Therapeutics, Inc. $500.00 06/04/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749043225
Principal investigator 1 Sage Therapeutics, Inc. $2,500.00 06/04/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749043227
Principal investigator 1 Sage Therapeutics, Inc. $500.00 06/04/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749043229
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 06/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906299
Principal investigator 1 Supernus Pharmaceuticals, Inc. $7,880.54 05/30/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749582665
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.00 05/29/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737082097
Principal investigator 1 Janssen Research & Development, LLC $8,034.00 05/28/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 719498535
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $41,438.59 05/26/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training CCT No dispute reported 06/30/2026 751189233
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,861.26 05/19/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 748383185
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,612.26 05/19/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-059 No dispute reported 06/30/2026 748383239
Principal investigator 1 Allergan, Inc. $2,096.65 05/14/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721275195
Principal investigator 1 Supernus Pharmaceuticals, Inc. $29,242.65 05/13/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749582557
Principal investigator 1 Eisai Inc. $1,600.00 05/12/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749134077
Principal investigator 1 Sage Therapeutics, Inc. $29,290.59 05/12/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749042899
Principal investigator 1 Janssen Research & Development, LLC $11,568.00 05/07/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 719498539
Principal investigator 1 Eisai Inc. $1,000.00 05/05/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749134229
Principal investigator 1 Eisai Inc. $250.00 05/05/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749134231
Principal investigator 1 Eisai Inc. $1,500.00 05/05/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749134237
Principal investigator 1 Janssen Research & Development, LLC $693.00 05/04/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 719498491
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 05/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906289
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.00 04/30/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737078137
Principal investigator 1 Supernus Pharmaceuticals, Inc. $5,901.85 04/28/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF SPN-812 ER FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 749582453
Principal investigator 1 Boehringer Ingelheim International GmbH $256.16 04/27/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906291
Principal investigator 1 ACADIA Pharmaceuticals Inc $56.97 04/24/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
ACP-103-055 No dispute reported 06/30/2026 748382987
Principal investigator 1 ACADIA Pharmaceuticals Inc $25.50 04/24/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
ACP-103-055 No dispute reported 06/30/2026 748382989
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,581.81 04/22/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 748382729
Principal investigator 1 ACADIA Pharmaceuticals Inc $15,977.32 04/22/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-059 No dispute reported 06/30/2026 748382795
Principal investigator 1 Allergan, Inc. $13,184.10 04/22/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721271917
Principal investigator 1 Supernus Pharmaceuticals, Inc. $56,877.98 04/17/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 749582285
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $149.50 04/16/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740106497
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 04/16/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740106499
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 04/16/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740106501
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $200.00 04/16/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740106503
Principal investigator 1 Allergan, Inc. $1,784.10 04/14/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721269769
Principal investigator 1 Sage Therapeutics, Inc. $22,404.33 04/14/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749042573
Principal investigator 1 Supernus Pharmaceuticals, Inc. $225.00 04/09/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 749582243
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 04/02/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906285
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 04/02/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906287
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 04/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906293
Principal investigator 1 Supernus Pharmaceuticals, Inc. $7,180.00 04/01/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 749582193
Principal investigator 1 Eisai Inc. $1,600.00 03/31/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133565
Principal investigator 1 Eisai Inc. $1,815.00 03/31/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133567
Principal investigator 1 Eisai Inc. $1,600.00 03/31/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133569
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.00 03/31/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737075451
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 03/26/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906321
Principal investigator 1 Eisai Inc. $1,665.00 03/26/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133635
Principal investigator 1 Eisai Inc. $1,600.00 03/26/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133637
Principal investigator 1 Janssen Research & Development, LLC $8,901.00 03/26/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 719498523
Principal investigator 1 ACADIA Pharmaceuticals Inc $4,327.84 03/23/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 748381969
Principal investigator 1 ACADIA Pharmaceuticals Inc $20,013.50 03/23/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-059 No dispute reported 06/30/2026 748381973
Principal investigator 1 Allergan, Inc. $90.00 03/19/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721266233
Principal investigator 1 Allergan, Inc. $16,679.15 03/19/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721266235
Principal investigator 1 Allergan, Inc. $1,500.05 03/16/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721264065
Principal investigator 1 Janssen Research & Development, LLC $3,126.00 03/16/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 719498485
Principal investigator 1 Sage Therapeutics, Inc. $8,921.25 03/11/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
217-MDD-303 No dispute reported 06/30/2026 749042079
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 03/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906319
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.00 02/28/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737072859
Principal investigator 1 Allergan, Inc. $86.00 02/27/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721261139
Principal investigator 1 Sage Therapeutics, Inc. $5,714.28 02/27/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
217-MDD-302 No dispute reported 06/30/2026 749041991
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,956.14 02/25/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 748381631
Principal investigator 1 Janssen Research & Development, LLC $9,623.00 02/24/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 719498528
Principal investigator 1 Sage Therapeutics, Inc. $6,500.00 02/20/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
217-MDD-302 No dispute reported 06/30/2026 749041803
Principal investigator 1 Sage Therapeutics, Inc. $2,000.00 02/20/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
217-MDD-302 No dispute reported 06/30/2026 749041805
Principal investigator 1 Sage Therapeutics, Inc. $131.32 02/20/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
217-MDD-302 No dispute reported 06/30/2026 749041807
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,000.00 02/14/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-042 No dispute reported 06/30/2026 748381389
Principal investigator 1 Allergan, Inc. $1,500.05 02/14/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721257175
Principal investigator 1 Eisai Inc. $2,769.00 02/07/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133363
Principal investigator 1 Eisai Inc. $1,075.00 02/07/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133365
Principal investigator 1 Eisai Inc. $2,769.00 02/07/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133367
Principal investigator 1 ACADIA Pharmaceuticals Inc $7,443.11 02/03/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 748381379
Principal investigator 1 Eli Lilly and Company $1,868.80 02/03/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 728744273
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 02/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906315
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.00 01/31/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737069033
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $43.30 01/30/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737068991
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24.35 01/30/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737068997
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $59.54 01/30/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737069003
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25.27 01/30/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737069009
Principal investigator 1 Sage Therapeutics, Inc. $76,536.36 01/29/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
217-MDD-303 No dispute reported 06/30/2026 749041565
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $187.19 01/29/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737068949
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $139.00 01/29/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737068955
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $89.73 01/29/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737068961
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12.90 01/29/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737068967
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $33.59 01/29/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737068969
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11.74 01/29/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737068971
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7.58 01/29/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737068973
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721251329
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721252593
Principal investigator 1 Eisai Inc. $1,600.00 01/28/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133247
Principal investigator 1 Eisai Inc. $3,371.00 01/28/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133249
Principal investigator 1 Eisai Inc. $3,117.00 01/28/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133251
Principal investigator 1 Eisai Inc. $1,600.00 01/28/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133305
Principal investigator 1 Eisai Inc. $1,600.00 01/28/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133307
Principal investigator 1 Eisai Inc. $2,648.10 01/28/2020 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133309
Principal investigator 1 Janssen Research & Development, LLC $693.00 01/24/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 719498487
Principal investigator 1 Janssen Research & Development, LLC $8,676.00 01/24/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 719498531
Principal investigator 1 Allergan, Inc. $1,842.00 01/22/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721249919
Principal investigator 1 Allergan, Inc. $6,964.45 01/22/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721249921
Principal investigator 1 Allergan, Inc. $700.00 01/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
PHASE IIA US POP W/ SOD (3125-201-002) No dispute reported 06/30/2026 721249115
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,612.24 01/20/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-059 No dispute reported 06/30/2026 748381133
Principal investigator 1 Allergan, Inc. $522.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721246207
Principal investigator 1 Allergan, Inc. $86.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721247029
Principal investigator 1 Allergan, Inc. $9,270.10 01/14/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721247251
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $201.28 01/10/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 737067743
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $198,842.21 01/09/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (TRIAL 405-201-00014) No dispute reported 06/30/2026 748803119
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $64,957.54 01/09/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 748803123
Principal investigator 1 Allergan, Inc. $90.00 01/06/2020 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721245421
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 01/01/2020 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 749906317